logo-loader
viewPRO MEDICUS LIMITED

Pro Medicus inks $8M deal with US health network

au_australian_dollar350_546e5d08446a3.jpg

Pro Medicus (ASX:PME) should trade higher after signing an A$8 million, seven-year contract with WellSpan Health – a large regional health network in the United States.

Under the agreement, PME's Visage 7 technology will be used throughout the WellSpan network for primary diagnosis, as well as clinical distribution of diagnostic images.

Visage 7 enables even the largest imaging organisations and health systems to transform the interpretation and delivery of medical images.

Visage 7 has a unique ability to deal with the extremely large image files created by modern radiology equipment.

The contract will see WellSpan use Pro Medicus’ Visage 7 technology as a core component of its new enterprise imaging platform for the next seven years, and possibly longer.

Impressively, WellSpan operates the region’s only accredited Level 1 Trauma Center and Primary Stroke Center, and spans 93 patient care locations and a network of four hospitals.

WellSpan serves a patient population of more than 650,000 people, has more than 11,000 employees, and is consistently ranked a top 100 US integrated healthcare network.

Earlier this year, PME signing another contract with another large US health network, again incorporating Visage 7 technology.

This contract covers a six-year term with a base contract value of $20 million, and potential upside as the technology is expanded throughout the health system.

Pro Medicus is also in a five year agreement with one of the world’s largest radiology groups, Virtual Radiologic.

The company has a global product platform, strong balance sheet backing and is capped at $100 million.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: PRO MEDICUS LIMITED

Price: 26.49 AUD

ASX:PME
Market: ASX
Market Cap: $2.75 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Electric vehicle sales to accelerate following coronavirus pandemic

Roskill analyst Jose Lazuen tells Proactive London's Andrew Scott severe falls were expected in EV sales but that European and Chinese policies coupled with consumer preferences have shown them to remain strong. He adds that policy is going to favour and push EV sales in certain jurisdictions...

1 day, 12 hours ago

2 min read